Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy

Clinical Pharmacokinetics

Volumn 48, Issue 10, 2009, Pages 677-683

  Ververs, F F Tessa ^a   Voorbij, Heronimus A M ^a   Zwarts, Petra ^b   Belitser, Svetlana V ^c   Egberts, Toine C G ^a,c   Visser, Gerard H A ^a   Schobben, Alfred F A M ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; HALOPERIDOL; MIRTAZAPINE; PAROXETINE;

ADULT; ANXIETY DISORDER; ARTICLE; BLOOD SAMPLING; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENOTYPE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL PLASMA; MOOD; PREGNANCY; PRIORITY JOURNAL; WEIGHT GAIN;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; DEPRESSION; DRUG MONITORING; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PAROXETINE; PHARMACOGENETICS; PREGNANCY; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349094422     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11318050-000000000-00000     Document Type: Article

References (39)

1. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008; 198 (2): 194.e1-5
2. Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 2005; 25 (1): 59-73
3. Bakker MK, Kolling P, van den Berg PB, et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population- based cohort study from the Netherlands. Br J Clin Pharmacol 2008; 65 (4): 600-606
4. Ververs T, Kaasenbrood H, Visser G, et al. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006; 62 (10): 863-870
5. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse ofmajor depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295 (5): 499-507
6. Sit DK, Perel JM, Helsel JC, et al. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008; 69 (4): 652-658
7. Hostetter A, Stowe ZN, Strader Jr JR, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000; 11 (2): 51-57
8. Kim J, Riggs KW, Misri S, et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol 2006; 61 (2): 155-163
9. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73 (4): 330-337
10. Carrillo JA, Dahl ML, Svensson JO, et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996; 60 (2): 183-190
11. Haffen E, Vandel P, Broly F, et al. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype. Pharmacopsychiatry 1999; 32: 232-234
12. Sindrup SH, Brøsen K, Hansen MG, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993; 15: 11-17
13. Kobayashi K, Ishizuka T, Shimada N, et al. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 1999; 27: 763-766
14. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 2002; 41: 1247-1266
15. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005; 33: 262-270
16. Kirchheiner J, Brøsen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype based dose recommendations for antidepressants: a first step towards subpopulation- specific dosages. Acta Psychiatr Scand 2001; 104: 173-192
17. Xu ZH, Wang W, Zhao XJ, et al. Evidence for involvement of polymorphic CYP2C19 and 2C9 in theN-demethylation of sertraline in human livermicrosomes. Br J Clin Pharmacol 1999; 48: 416-423
18. Rasmussen BB, Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Drug Monit 2002; 22: 143-154
19. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3 (2): 229-243
20. Hamelin BA, Turgeon J, Vallee F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996; 60 (5): 512-521
21. Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60 (5): 329-336
22. Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51 (3): 288-295
23. Spigset O, Granberg K, Hagg S, et al. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 1997; 52 (2): 129-133
24. Tamminga WJ,Wemer J, Oosterhuis B, et al. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 2001; 57 (10): 717-722
25. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic- based approach. Clin Pharmacokinet 2005; 44 (10): 989-1008
26. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293 (19): 2372-2383 (Pubitemid 40676760)
27. Cox JL, Chapman G, Murray D, et al. Validation of the Edinburgh Postnatal Depression Scale (EPDS) in non-postnatal women. J Affect Disord 1996; 39 (3): 185-189
28. Blakesley JD, Howse CG, Spencer-Peet J, et al. An improved method for measurement of common tricyclic antidepressant drugs and their metabolites using normal phase HPLC. Ann Clin Biochem 1986; 23 (Pt 5): 552-558
29. Sauvage FL, Gaulier JM, Lachatre G, et al. A fully automated turbulentflow liquid chromatography-tandem mass spectrometry technique for monitoring antidepressants in human serum. Ther Drug Monit 2006; 28 (1): 123-130
30. Schenk PW, van Fessem MA, Verploegh-Van Rij S, et al. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 2008; 13 (6): 597-605
31. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 2005; 192 (2): 633-639
32. Wadelius MM, Darj E, Frenne G, et al. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997 Oct; 62 4: 400-407
33. Dickmann LJ, Tay S, Senn TD, et al. Changes in maternal liver CYP2C and CYP2D expression and activity during rat pregnancy. Biochem Pharmacol 2008; 75 (8): 1677-1687
34. Tasker TC, Kaye CM, Zussman BD, et al. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand Suppl 1989; 350: 152-155
35. Evans J, Heron J, Francomb H, et al. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001; 323 (7307): 257-260 (Pubitemid 32729111)
36. Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80 (1): 18-27
37. Oberlander TF, WarburtonW,Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population- based study. Br J Psychiatry 2008; 192 (5): 338-343
38. Noorlander CW, Ververs FF, Nikkels PG, et al. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS ONE 2008; 3 (7): e2782
39. DeVane CL, Stowe ZN, Donovan JL, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol 2006; 20 (4 Suppl.): 54-59